Filing of The Day: Marinus Pharmaceuticals Inc: Sofinnova Venture Partners Vi L P Opened Big New Position

Filing of The Day: Marinus Pharmaceuticals Inc: Sofinnova Venture Partners Vi L P Opened Big New Position

The New Sofinnova Venture Partners Vi L P Holding in Marinus Pharmaceuticals Inc

Sofinnova Venture Partners Vi L P filed with the SEC SC 13D/A form for Marinus Pharmaceuticals Inc. The form can be accessed here: 000114420416135851. As reported in Sofinnova Venture Partners Vi L P’s form, the filler as of late owns 4.0% or 728,975 shares of the -company.

Marinus Pharmaceuticals Inc stake is a new one for the and it was filed because of activity on November 15, 2016. We feel this shows Sofinnova Venture Partners Vi L P’s positive view for the stock.

Marinus Pharmaceuticals Inc Institutional Sentiment

Latest Security and Exchange filings show 34 investors own Marinus Pharmaceuticals Inc. The institutional ownership in Q3 2015 is low, at 19.83% of the outstanding shares. This is increased by 59290 the total institutional shares. 3907536 were the shares owned by these institutional investors. In total 12 funds opened new Marinus Pharmaceuticals Inc stakes, 10 increased stakes. There were 3 that closed positions and 7 reduced them.

Harvey Capital Management Inc is an institutional investor bullish on Marinus Pharmaceuticals Inc, owning 25500 shares as of Q3 2015 for 0.08% of its portfolio. Nathan Fischel Dafna Capital Management Llc owns 22319 shares or 0.18% of its portfolio. CA Palo Alto Investors Llc have 0.02% of their stock portfolio for 59017 shares. Further, Iguana Healthcare Management Llc reported stake worth 0.25% of its US stock portfolio. The NY New Leaf Venture Partners Llc owns 704572 shares. Marinus Pharmaceuticals Inc is 5.10% of the manager’s US portfolio.

Business Profile

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment decreased to 1.08 in 2016 Q2. Its down 0.09, from 1.17 in 2016Q1. The ratio is negative, as 7 funds sold all Marinus Pharmaceuticals Inc shares owned while 5 reduced positions. 5 funds bought stakes while 9 increased positions. They now own 6.42 million shares or 11.80% less from 7.28 million shares in 2016Q1.

Dafna Mngmt Lc accumulated 90,237 shares or 0.09% of the stock. The California-based Blackrock Fund Advisors has invested 0% in Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Goldman Sachs Grp Incorporated holds 0% of its portfolio in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) for 12,415 shares. The Israel-based Sphera Funds Limited has invested 0.39% in Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Tradewinds Ltd Limited Liability Company holds 0.01% of its portfolio in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) for 6,000 shares. The Texas-based Bridgeway Mngmt has invested 0% in Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Geode Capital Mgmt Ltd holds 0% of its portfolio in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) for 55,614 shares. Fincl Bank Of Mellon Corp accumulated 0% or 16,474 shares. Morgan Stanley holds 0% or 1,200 shares in its portfolio. The Massachusetts-based Putnam Invs Ltd Liability Com has invested 0% in Marinus Pharmaceuticals Inc (NASDAQ:MRNS). Blackrock Institutional Na holds 0% of its portfolio in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) for 22,956 shares. Moreover, Northern has 0% invested in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) for 21,108 shares. Vanguard Group Inc accumulated 0% or 283,380 shares. Orbimed Ltd Llc, a New York-based fund reported 867,600 shares. Palo Alto Investors Ltd Llc holds 0.01% or 63,517 shares in its portfolio.

Insider Transactions: Since July 22, 2016, the stock had 0 insider purchases, and 6 selling transactions for $2.08 million net activity. On Wednesday, August 3 the insider Canaan VII LP sold $218,375. 750,683 shares with value of $1.04M were sold by Mehra Anand on Thursday, October 20.

About 2.07M shares traded hands or 380.91% up from the average. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has declined 82.62% since April 20, 2016 and is downtrending. It has underperformed by 87.18% the S&P500.

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $22.74 million. The Firm focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It currently has negative earnings. The Company’s clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Ratings Coverage

Out of 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. $21 is the highest target while $2.50 is the lowest. The $12.50 average target is 986.96% above today’s ($1.15) stock price. Marinus Pharmaceuticals has been the topic of 9 analyst reports since August 5, 2015 according to StockzIntelligence Inc. RBC Capital Markets initiated Marinus Pharmaceuticals Inc (NASDAQ:MRNS) on Thursday, December 17 with “Outperform” rating. The stock of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) earned “Buy” rating by Jefferies on Wednesday, August 10. The stock of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has “Outperform” rating given on Friday, October 30 by Oppenheimer. The company was maintained on Wednesday, August 5 by Oppenheimer. The stock of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) earned “Buy” rating by Jefferies on Tuesday, November 17. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, March 8 report. Jefferies maintained it with “Buy” rating and $2.50 target price in Tuesday, June 14 report. The stock of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) has “Sector Perform” rating given on Tuesday, June 14 by RBC Capital Markets. Oppenheimer downgraded Marinus Pharmaceuticals Inc (NASDAQ:MRNS) on Tuesday, June 14 to “Perform” rating.

More recent Marinus Pharmaceuticals Inc (NASDAQ:MRNS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on May 16, 2014. Also 247Wallst.com published the news titled: “Why Marinus Pharmaceuticals Shares Are Sliding” on June 13, 2016. Quotes.Wsj.com‘s news article titled: “News Marinus Pharmaceuticals Inc.MRNS” with publication date: July 27, 2014 was also an interesting one.

According to Zacks Investment Research, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment